SCHEMBL2858941

SCHEMBL2858941

COc1ccc(Cn2c(=O)c3c(N)n(-c4cc(OC)c(Oc5ccccc5)cc4C)nc3c3ccc(OC(C)C)cc32)cc1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.38
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
KMT2A Q03164 1/20 0.38
PLA2G10 O15496 1/20 0.37
P2RX7 Q99572 2/20 0.37
PLA2G2A P14555 2/20 0.36
S1PR3 Q99500 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
BLM P54132 1/20 0.35
POLB P06746 2/20 0.35
PDE1A P54750 3/20 0.34
PDE1B Q01064 3/20 0.34
PDE1C Q14123 3/20 0.34
THRB P10828 1/20 0.34
TP53 P04637 2/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2857641 0.91 PDE1B (0.38) GAAMEN1MAPTMAPK1KMT2A
SCHEMBL2862981 0.90 PLA2G10 (0.39) GAAMEN1MAPK1KMT2APLA2G10
SCHEMBL2862282 0.90 P2RX4 (0.42) GAAMEN1MAPTKMT2ASMN1; SMN2
SCHEMBL2856173 0.88 MEN1 (0.41) GAAMEN1MAPTMAPK1KMT2A
SCHEMBL2867619 0.86 BCL2 (0.40) GAAMEN1MAPTMAPK1KMT2A
SCHEMBL2861122 0.86 PDE1A (0.39) GAAMEN1MAPTMAPK1KMT2A
SCHEMBL2862709 0.84 RXFP1 (0.42) MAPTPLA2G10P2RX7S1PR3POLB
SCHEMBL2866691 0.83 PIK3R1 (0.40) MEN1MAPTKMT2APLA2G10P2RX7
SCHEMBL2865416 0.83 S1PR3 (0.41) GAAMEN1MAPTMAPK1KMT2A
SCHEMBL2863040 0.83 MAPT (0.43) GAAMEN1MAPTMAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 GAA 4868/4885MEN1 3903/4885MAPT 4583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.